Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technologyon January 19, 2021 at 8:00 am
PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), ...
- Cureduchenne Launches Initiative To Prioritize Duchenne Community Needs For COVID-19 Vaccine Rollouton January 14, 2021 at 4:01 pm
CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a new initiative centered on the COVID-19 vaccine rollout and Duchenne ...
- Duchenne Muscular Dystrophy Drugs Market 2021 Share, Size Global Growth Analysis, Trends, Industry Analysis, Key Players and Forecast to 2025on January 12, 2021 at 6:38 am
Global Duchenne Muscular Dystrophy Drugs Market Research Report focuses on market size, status and forecast 2020-2025, along with this report also focuses on market opportunities and treats, risk ...
- Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Studyon January 9, 2021 at 4:00 pm
In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 -- Preclinical Data Further Validate FORCE™ Platform; ...
- CureDuchenne Congratulates Pfizer on Dosing First Patient in Phase III Clinical Trial for Duchenne Muscular Dystrophyon January 8, 2021 at 2:57 pm
CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), celebrates Pfizer Inc’s (NYSE: ...
- Sarepta Tanks On Likely 2-Year Delay For Muscular Dystrophy Gene Therapyon January 8, 2021 at 2:30 pm
Sarepta Therapeutics' (SRPT) gene therapy targeting muscular dystrophy could be delayed for two years, an analyst said Friday as SRPT stock ...
- Duchenne-focused biotech Sarepta loses $6.5B in value after trial failon January 8, 2021 at 4:03 am
Shares of Sarepta Therapeutics Inc., which employs more than 600 people in Massachusetts, were cut in half in after-hours trading Thursday night after a highly anticipated gene therapy for Duchenne ...
- Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcomeon January 7, 2021 at 1:50 pm
The study failed to produce statistically significant improvements in muscle function for all patients after one year.
- Parent Project Muscular Dystrophy Announces 2021 Certified Duchenne Care Center Inter-Institutional Collaboration Grant Programon January 7, 2021 at 7:00 am
PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) is ...
- Pfizer initiates dosing in the study for rare muscular disorderon January 7, 2021 at 4:34 am
Pfizer (NYSE:PFE) says that it has dosed the first participant in Phase 3 global, multicenter trial evaluating its gene therapy candidate PF-06939926 in boys with Duchenne muscular dystrophy (“DMD”).
via Bing News